References
- Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–352.
- Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331:637–642.
- Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2011;10(Suppl 2):S79–81.
- Horsley AR, Davies JC, Gray RD, et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax. 2013;68:532–539.
- Ordoñez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:1471–1475.
- Colombo C, Costantini D, Rocchi A, et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol. 2005;40:15–21.
- Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med. 2007;175:822–828.
- Gray RD, Imrie M, Boyd AC, et al. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros. 2010;9:193–198.
- Shoki AH, Mayer-Hamblett N, Wilcox PG, et al. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest. 2013;144:1659–1670.
- Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121:219–225.
- Girón-Moreno RM, Justicia JL, Yamamoto S, et al. Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis. BMC Pulm Med. 2014;14:150.
- Sagel SD, Thompson V, Chmiel JF, et al. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. Ann Am Thorac Soc. 2015;12:708–717.
- McKiernan PJ, Greene CM. MicroRNA dysregulation in cystic fibrosis. Mediators Inflamm. 2015;2015:529642.
- Cook NL, Pereira TN, Lewindon PJ, et al. Circulating microRNAs as noninvasive diagnostic biomarkers of liver disease in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60:247–254.
- Twigg MS, Brockbank S, Lowry P, et al. The role of serine proteases and antiproteases in the cystic fibrosis lung. Mediators Inflamm. 2015;2015:293053.
- Quon BS, Dai DLY, Hollander Z, et al. Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry. Thorax. 2016;71:216–222.
- Reid PA, McAllister DA, Boyd AC, et al. Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis. Am J Respir Crit Care Med. 2015;191:233–236.
- Ratjen F, Saiman L, Mayer-Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest. 2012;142:1259–1266.
- Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc. 2007;4:406–417.
- Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet Lond Engl. 2002;360:1715–1721.
- Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163–2173.
- Kumar RB, Goren ND, Stark DE, et al. Automated integration of continuous glucose monitor data in the electronic health record using consumer technology. J Am Med Inform Assoc JAMIA. 2016;23:532–537.